Durect says Voyager ends trial of Alzheimer's drug�|�Reuters.com

Durect says Voyager ends trial of Alzheimer's drug�|�Reuters.com: "Durect Corp. (DRRX.O: Quote, Profile, Research) on Thursday said that Voyager Pharmaceutical is ending its late-stage trials of an Alzheimer's disease treatment that uses Durect's sustained-release technology.

Durect, which specializes in drug-delivery technology, said Voyager had ended the Phase III trials of its drug, called Memryte, 'in order to get an earlier look at potential efficacy' from over 600 patients."